Abstract Introduction/Objective Physicians often rely on Cerebrospinal Fluid (CSF) cytology, chemistry, and culture. While cheap, these methods lack high sensitivity/specificity or have long turnaround times. PCR evaluation of CSF has become more common and is often touted as a way to save money, decrease turnaround times and quickly target antibiotics. PCR systems may cost $200,000, with $150 in disposables per test. As a new, fast, test it may be over ordered. Methods/Case Report Case-control study using retrospective chart review. All adults, aged 18 and over, who had undergone both PCR based testing and cytochemical testing between 3/1/2017 and 9/7/2019 were included. Results (if a Case Study enter NA) From 3/1/2017-9/7/2019, there were 381 available PCR results for adult GWUH patients. Demographic data showed that the patient sample was majority black (195/320, 60.94%), had an average age of 49.8 ± 17.2, and was majority female (172/320, 53.75%). The PCR results were 85.31% negative (273/320) and the CSF cultures were 94.38% negative. The most common PCR positive organism was Varicella zoster virus (11/47 positive results) and the most common CSF culture organism was Streptococcus pneumoniae (5/18 positive cultures). Conclusion In a population with clinical symptoms and at least 1 abnormality on CSF analysis, 6.5 tests were run for every positive PCR test. No single variable was found to significantly predict PCR results. Within a high initial cost, a disposable cost of $150 per test and detection rate of 14.7%, the cost to detect a single positive test by PCR could approach $4,500. PCR should be used judiciously following history, physical exam and standard CSF workup, rather than as a screening tool.
Read full abstract